纤维肌痛综合征 中国就医指南

Fibromyalgia Syndrome (FMS) is a chronic, non-inflammatory, central nervous system disorder characterized by widespread musculoskeletal pain, fatigue, sleep disturbances, cognitive dysfunction ('fibro fog'), and heightened sensory sensitivity. Unlike autoimmune or degenerative rheumatic diseases, FMS does not involve joint inflammation, tissue damage, or autoantibodies; rather, it reflects abnormal central pain processing—specifically, amplified pain signaling due to dysregulation in descending inhibitory pathways and increased excitatory neurotransmitter activity (e.g., substance P, glutamate) in the spinal cord and brain. Functional neuroimaging studies consistently show hyperactivity in pain-processing regions (e.g., anterior cingulate cortex, insula) and reduced connectivity in default mode networks. The pathogenesis is multifactorial: genetic predisposition (e.g., polymorphisms in serotonin transporter and catechol-O-methyltransferase genes), early-life stress, physical or psychological trauma, infections (e.g., Epstein-Barr virus), and comorbid conditions like depression or irritable bowel syndrome act as potential triggers or amplifiers. Epidemiologically, FMS affects approximately 2–4% of the global adult population, with a striking female-to-male ratio of 7:1–9:1. Prevalence peaks between ages 30 and 55 but can occur across the lifespan—including in adolescents and older adults. Risk factors include female sex, family history, mood disorders (especially major depressive disorder and anxiety), obesity (BMI ≥30), sedentary lifestyle, smoking, and occupational stressors involving repetitive strain or emotional exhaustion. Importantly, FMS is frequently underdiagnosed or misattributed to psychiatric illness, leading to diagnostic delays averaging 2–5 years. Its impact on quality of life is profound: patients report significantly lower physical functioning than those with osteoarthritis or rheumatoid arthritis, higher rates of work disability (up to 30% unemployment), impaired social participation, and elevated risks of depression, anxiety, and suicidal ideation. Sleep architecture disruption—particularly reduced stage N3 (deep) sleep and alpha-delta intrusion—is both a hallmark and a contributor to symptom persistence. While no definitive biomarker exists, diagnosis remains clinical, guided by the 2016 American College of Rheumatology (ACR) criteria emphasizing widespread pain index (WPI) and symptom severity scale (SSS), excluding other mimicking conditions (e.g., hypothyroidism, lupus, myopathies). Multidisciplinary management—not cure-focused but symptom-modulating—is essential for functional improvement and long-term adaptation.

# 纤维肌痛综合征治疗方案与费用明细（风湿免疫科）

一、非手术/保守治疗（一线首选）

• •适用人群：确诊患者，无严重共病或中枢敏化危象者
• •药物治疗（医保乙类）：

- 度洛西汀（60 mg/d）：260–490元/月 - 阿米替林（10–25 mg/d）：15–35元/月

• •物理治疗（医保甲类）：

• •检查费：血常规、ESR、CRP、甲状腺功能、维生素D检测等基础筛查：280–420元

二、手术/微创/介入方案

• •本病无根治性手术指征，不推荐任何外科或介入操作。纤维肌痛为中枢敏化性疼痛综合征，非结构性病变，所有“神经阻滞”“脊髓刺激”“射频消融”等属超适应证，三甲医院风湿免疫科不予开展。

三、复杂/耐药/并发症方案

• •适用人群：合并重度抑郁、睡眠障碍、肠易激或难治性疼痛（VAS≥7分持续＞6月）
• •多学科整合管理（MDT门诊）：风湿科+心理科+康复科联合干预，含CBT认知行为治疗（8次）、睡眠评估及个体化镇痛优化：3,200–5,600元/疗程
• •检查升级：脑脊液5-HT代谢物检测、定量感觉测试（QST）：1,800–2,900元

四、方案快速选择指南

• •预算有限（＜2,000元/年）：阿米替林+医保理疗+基础筛查
• •中等预算（3,000–8,000元/年）：度洛西汀+普瑞巴林+MDT初筛
• •复杂需求（＞10,000元/年）：全程MDT管理+QST评估+长期随访